Evidence map›Paper›PMID 35979578›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2022

Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.

Sayaka Ohno, Kiyohito Hayashi, Ryo Shimizu, Akihiro Ishii, Hiroaki Tanaka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sayaka OhnoDepartment of Hematology, Asahi General Hospital, Chiba, Japan.
Kiyohito HayashiDepartment of Hematology, Asahi General Hospital, Chiba, Japan.
Ryo ShimizuDepartment of Hematology, Asahi General Hospital, Chiba, Japan.
Akihiro IshiiDepartment of Transfusion Medicine, Asahi General Hospital, Chiba, Japan.
Hiroaki TanakaDepartment of Hematology, Asahi General Hospital, Chiba, Japan.
Asahi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral blood stem cell harvest (PBSCH) is a crucial procedure for autologous stem cell transplantation in patients with multiple myeloma. We herein report a retrospective study to verify the usefulness of bortezomib and high-dose cyclophosphamide therapy (Bor-HDCY) as a conditioning regimen for PBSCH. Thirty-three patients were evaluated. The median age at the first apheresis was 61 (interquartile range, 53-64) years old, and 18 (54.5%) patients were male. Bor-HDCY was performed in 15 patients, and HDCY was performed in 18. In the patients who underwent Bor-HDCY, the CD34

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaPeripheral Blood Stem CellsAntigens, CD34BortezomibCyclophosphamideDexamethasoneFemaleHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHumansLenalidomideMaleMiddle AgedRetrospective StudiesTransplantation, AutologousAntigens, CD34BortezomibCyclophosphamideDexamethasoneLenalidomideautologous peripheral blood stem cell harvestbortezomibconditioning regimenhigh-dose cyclophosphamide therapymultiple myeloma

Identifiers

PMID35979578
PMCPMC9635030
OpenAlexW4292340193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.